Reishi

Reishi operates through a remarkably broad range of mechanisms reflecting its complex phytochemistry (over 400 identified bioactive compounds). The major mechanistic pathways are immune modulation, anti-cancer effects, anti-inflammation, cardiovascular/metabolic effects, hepatoprotection, and central nervous system modulation.

1. Immune modulation via β-glucans and polysaccharides. Reishi polysaccharides — especially β-(1,3)/(1,6)-glucans — are the principal immunomodulators. They activate innate immune cells through pattern recognition receptors including Dectin-1 (a C-type lectin on macrophages, dendritic cells, and neutrophils), complement receptor 3 (CR3/CD11b), and Toll-like receptors (TLR2, TLR4, TLR6). This activation triggers: (a) increased phagocytic activity of macrophages and neutrophils, (b) enhanced NK cell cytotoxicity against tumor and virus-infected cells, (c) increased production of IL-1, IL-6, IL-12, IFN-γ, TNF-α, and other pro-inflammatory cytokines during active infection, (d) maturation and activation of dendritic cells, which in turn prime T cell responses, and (e) enhanced antibody production by B cells. Importantly, reishi's immune effect is modulation rather than simple stimulation — in autoimmune and chronic inflammatory states, reishi can also dampen excessive Th1 or Th17 activity through regulatory T cell (Treg) enhancement and anti-inflammatory cytokine modulation.

2. Anti-tumor effects of triterpenoids (ganoderic acids). The ganoderic acids, particularly ganoderic acid T, ganoderic acid D, ganoderic acid A, and ganoderic acid F, have demonstrated direct anti-tumor activity in cell culture and animal models through multiple mechanisms: (a) induction of apoptosis via mitochondrial pathways (caspase 3/9 activation, cytochrome c release), (b) cell cycle arrest at G1/S or G2/M checkpoints, (c) inhibition of angiogenesis (reduced VEGF, blocked tumor neovascularization), (d) inhibition of metastasis (reduced matrix metalloproteinases, blocked invasion and migration), (e) induction of differentiation in leukemia cells, and (f) enhancement of chemotherapy sensitivity while potentially reducing chemotoxicity in normal cells. Ganoderic acids synergize with several chemotherapeutic agents in preclinical models.

3. Protein-mediated immune modulation via LZ-8. Reishi produces a unique protein called LZ-8 (Ling Zhi-8), a fungal immunomodulatory protein that acts as a T cell co-stimulator — improving T cell activation in response to antigens while potentially modulating autoimmune responses. LZ-8 has been studied for both oncology adjunctive use and for potential applications in organ transplant tolerance induction (though the immunomodulatory role here is complex).

4. Anti-inflammatory effects. Reishi triterpenoids inhibit NF-κB activation and downstream pro-inflammatory mediators (COX-2, iNOS, TNF-α, IL-6). They also activate Nrf2/ARE antioxidant pathways, improving cellular antioxidant defenses. This dual pathway inhibition of NF-κB combined with activation of Nrf2 is reminiscent of other natural anti-inflammatory compounds like curcumin and resveratrol.

5. Antioxidant activity. Reishi contains potent antioxidants including its triterpenoids, polysaccharides, ergothioneine (which accumulates in the fruiting body), and various phenolics. These directly scavenge reactive oxygen species (ROS) and indirectly improve endogenous antioxidant enzyme production (SOD, catalase, glutathione peroxidase) through Nrf2 activation. Reduced oxidative damage is implicated in reishi's neuroprotective, hepatoprotective, and cardioprotective effects.

6. Cardiovascular effects. Reishi influences cardiovascular function through: (a) mild antihypertensive effects via ACE inhibition and NO enhancement, (b) antiplatelet activity (especially from certain triterpenoids and adenosine content — clinically relevant for bleeding risk assessment), (c) modest cholesterol-lowering effects via reduced HMG-CoA reductase activity and enhanced LDL receptor expression, and (d) anti-atherosclerotic effects through reduced oxidized LDL and improved endothelial function.

7. Hepatoprotective effects. Reishi shows hepatoprotection in models of toxin-induced liver injury (carbon tetrachloride, alcohol, acetaminophen) through: (a) reduced oxidative stress via Nrf2 activation, (b) reduced inflammatory cytokine release, (c) inhibition of hepatic stellate cell activation (reducing fibrosis), and (d) enhanced mitochondrial function. Multiple clinical studies have reported improvements in hepatitis B markers and liver enzyme levels with reishi preparations in chronic hepatitis.

8. Sleep-promoting and anxiolytic effects. Reishi has a notable calming effect attributed to multiple mechanisms: (a) GABA-A receptor modulation by reishi triterpenoids (though less potent than pharmaceutical benzodiazepines), (b) adenosine-mediated sleep-promoting effects (reishi contains adenosine and nucleosides), (c) reduction of cortisol and HPA-axis activity, and (d) modulation of serotonin signaling. Traditional use recommends reishi before bed for precisely this reason.

9. Anti-allergic effects. Reishi extracts have been shown to inhibit histamine release from mast cells and basophils, with potential benefits in allergic rhinitis, asthma, and atopic dermatitis. The mechanism involves direct effects on mast cell degranulation and modulation of IgE-mediated responses.

10. Neuroprotective effects. Preclinical studies suggest reishi polysaccharides and triterpenoids have neuroprotective effects in models of Alzheimer's disease, stroke, and Parkinson's disease through: (a) reduction of β-amyloid toxicity, (b) enhancement of cholinergic signaling, (c) reduction of neuroinflammation via microglial modulation, (d) BDNF upregulation, and (e) mitochondrial protection. Human evidence for neurological indications remains preliminary.

11. Anti-diabetic effects. Reishi polysaccharides modulate glucose homeostasis through: (a) improved insulin sensitivity (enhanced insulin receptor signaling), (b) modest inhibition of α-glucosidase (reducing post-meal glucose spikes), (c) preservation of pancreatic β-cell function, and (d) modulation of gut microbiota affecting glucose absorption. Clinical effects are modest but may complement standard diabetes management.

12. HPA-axis and adaptogenic effects. Like other adaptogens, reishi appears to normalize stress hormone responses — reducing elevated cortisol in chronic stress while potentially supporting adrenal function in exhaustion states. This is the classical "adaptogen" pattern shared with Ashwagandha and Rhodiola.

Reishi (scientific name Ganoderma lucidum, though the species most commonly cultivated and studied in East Asia is now properly recognized as Ganoderma lingzhi following a 2012 taxonomic revision) is a polypore mushroom known in Chinese as lingzhi (Θ¥êΦè¥, "spirit plant" or "mushroom of immortality"), in Japanese as reishi (Θ£èΦè¥) or mannentake ("10,000-year mushroom"), in Korean as yeongji (∞ÿü∞ºÇ), and in Vietnamese as linh chi. It holds perhaps the most exalted position in East Asian herbal medicine — the Shen Nong Ben Cao Jing (the Divine Farmer's Classic of Materia Medica, compiled around 200 BCE and considered the oldest Chinese materia medica) classified lingzhi in the highest category of "superior herbs" associated with prolonging life, improving vital energy (qi), strengthening cardiac function, improving memory, and nourishing the spirit (shen). For over 2,000 years, reishi has been symbolic of spiritual potency, longevity, divine power, and success in traditional Chinese, Japanese, and Korean culture — appearing in imperial robes, religious paintings, literary works, and traditional medicine preparations reserved for emperors and aristocracy. The distinctive kidney-shaped, red-brown, glossy-varnished cap of wild reishi (which grows on dead and dying hardwood trees, especially hemlock, oak, and plum) was so prized in wild form that it commanded extraordinary prices before commercial cultivation techniques were perfected in the 1970s.

Unlike many traditional medicinal mushrooms whose modern preparation relies on ordinary cultivation, reishi has benefited from decades of scientific horticultural refinement. Modern commercial reishi is grown in controlled conditions on hardwood logs, sawdust, or grain substrate, with different growing conditions producing different bioactive profiles. Six color varieties of Ganoderma are recognized in traditional Chinese medicine, each with slightly different proposed uses — red reishi (chizhi), black reishi (heizhi), blue reishi (qingzhi), white reishi (baizhi), yellow reishi (huangzhi), and purple reishi (zizhi) — though red reishi (Ganoderma lucidum/lingzhi) is by far the most commonly cultivated, studied, and commercialized form. Some specialty producers also cultivate Ganoderma sinense (purple-black variety) and Ganoderma applanatum (artist's conk, the "cloud mushroom"), though these are less common in commercial supplements.

Chemically, reishi is extraordinarily complex, containing over 400 identified bioactive compounds. The two classes of greatest pharmacological interest are: (1) triterpenoids, particularly the ganoderic acids (at least 150 different ganoderic acids have been identified, with ganoderic acids A, B, C, D, F, H, K, S, and T being most studied) — these are the compounds responsible for reishi's characteristic bitter taste and contribute to anti-cancer, anti-inflammatory, hepatoprotective, and cardiovascular effects; and (2) polysaccharides, particularly β-(1,3)/(1,6)-glucans and heteropolysaccharides — these drive reishi's immune-modulating effects and are the basis for several pharmaceutical-grade reishi preparations used as cancer chemotherapy adjuncts in Japan, Korea, and China. Additional bioactives include sterols (ergosterol and its derivatives), proteins (including LZ-8, a fungal immunomodulatory protein), alkaloids, nucleotides, and phenolic compounds. The ratio of triterpenoids to polysaccharides varies dramatically based on: (a) which part of the mushroom is used (fruiting body, spores, or mycelium), (b) extraction method (hot water vs alcohol vs dual extraction), and (c) cultivation conditions — making product quality assessment challenging for consumers.

The proposed clinical applications of reishi span several domains: (1) Cancer adjunctive therapy — the single most substantial clinical use in Asia, where pharmaceutical-grade reishi preparations (like the Japanese product Krestin/PSK and the more pure reishi-derived polysaccharide products) are prescribed alongside chemotherapy and radiation to reduce side effects and potentially improve outcomes. (2) Immune function — both immune enhancement (in infection-prone, immunocompromised, or aging populations) and immune modulation (in allergies, autoimmune tendencies, and chronic inflammation). (3) Sleep and stress — reishi has a notable sedating, calming effect and is traditionally used before bed; modern research supports mild anxiolytic and sleep-promoting effects. (4) Cardiovascular health — traditional use for "calming the heart," with modern evidence for modest blood pressure, cholesterol, and platelet-aggregation effects. (5) Liver support — hepatoprotective effects in various liver injury models; traditional use in chronic hepatitis. (6) General longevity and anti-aging — the most speculative but traditionally central claim. (7) Diabetes — modest evidence for glucose-lowering effects. (8) Respiratory conditions — traditional use in chronic cough, asthma, and bronchitis.

The human clinical evidence for reishi is moderate in volume but variable in quality, with Asian-language studies predominating. The most strong evidence exists for cancer adjunctive use. A 2016 Cochrane systematic review (Jin et al., PMID 27045603) analyzed 5 randomized controlled trials (373 participants) of Ganoderma lucidum as adjunct to chemotherapy/radiotherapy. The review concluded that reishi adjunctive therapy may increase tumor response rates (RR 1.50), improve functional status and quality of life, and improve immune parameters (CD3, CD4, CD8, NK cell activity) compared with standard cancer treatment alone. The authors noted that most trials were small, conducted in China, and had methodological limitations, but that the consistent direction of benefit warranted further rigorous investigation. In Japan and China, reishi-derived products like Krestin (PSK/PSP) from Coriolus versicolor (Turkey Tail — related to but not the same as reishi) are actually prescribed as pharmaceutical products alongside chemotherapy for colorectal, gastric, and lung cancers, with evidence of improved survival in some cases.

The sleep/stress evidence is preliminary but supportive. A small randomized trial (Zhao et al. 2012) in fatigued patients showed improvements in fatigue, depression, and quality of life. Multiple smaller studies in breast cancer survivors, chronic fatigue patients, and anxiety/stress populations have reported improvements in sleep quality and reductions in subjective fatigue. A 2019 systematic review of reishi for neurasthenia and fatigue concluded that evidence is suggestive but limited by trial size and methodology.

For cardiovascular effects, Gao et al. 2004showed reishi extract modestly reduced blood pressure, total cholesterol, and LDL-C in a 12-week trial. However, a 2015 Cochrane review (Klupp et al.) of Ganoderma for cardiovascular risk factors was less enthusiastic, concluding that current evidence for routine use is limited despite biological plausibility.

Where does reishi fit honestly in the therapeutic landscape? For cancer patients, reishi may be considered as an adjunctive option alongside (never in place of) standard oncology care, with oncologist awareness and monitoring — particularly for its potential effects on platelet function and immune markers. For healthy adults seeking general immune support, longevity tuning, sleep/stress management, or as a traditional adaptogen, reishi is a reasonable, well-tolerated option with moderate supporting evidence. It is NOT a substitute for evidence-based cancer therapy, antihypertensive medication, sleep medications (for clinically diagnosed insomnia), or mental health treatment. It sits comfortably alongside Cordyceps as a performance/respiratory mushroom, Lion's Mane as a cognitive mushroom, Chaga as an antioxidant mushroom, and Turkey Tail as an immune mushroom — forming a traditional "functional mushroom" framework in modern Western nutraceutical practice.

Safety with reishi is generally excellent at standard supplemental doses, though several considerations warrant attention. The most common adverse effect is mild GI upset. Rare but documented risks include hepatotoxicity (particularly with powdered, unextracted reishi fruiting body taken in large doses over extended periods — two case reports of fatal fulminant hepatitis have been associated with high-dose powder), allergic reactions, and antiplatelet effects. The pharmacologically active principles (especially triterpenoids) are significantly better extracted by dual extraction (hot water + alcohol) than by either method alone, and consumers should prefer dual-extracted fruiting body tinctures or standardized extracts (standardized to triterpenoid and/or polysaccharide content) over unextracted reishi powder.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Reishi Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility